Navigation Links
Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009
Date:3/25/2009

LEXINGTON, Mass., March 25 /PRNewswire/ -- Endo Pharmaceuticals Solutions Inc. (formerly known as Indevus Pharmaceuticals, Inc.) today commenced an offer to purchase any or all of its outstanding 6.25% Convertible Senior Notes due 2009 in accordance with the indenture governing the Notes, as a result of the acquisition of Indevus by Endo Pharmaceuticals Holdings. The offer to purchase the Notes is scheduled to expire at 5:00 p.m., Eastern time, on April 22, 2009.

In the Notice of Change of Control and Offer to Purchase issued today, Endo Pharmaceuticals Solutions notified the holders of the Notes that the acquisition of approximately 77.972% of Indevus Common Stock by Endo Pharmaceuticals Holdings upon the closing of the initial offering period of the related tender offer on February 23, 2009, the election of a majority of new directors to the Indevus board of directors and the merger whereby Indevus, under its new name, Endo Pharmaceuticals Solutions, became a wholly-owned subsidiary of Endo Pharmaceuticals Holdings each resulted in a "change of control" (as defined in the indenture) and that each holder has the right to require Endo Pharmaceuticals Solutions to purchase its Notes. Pursuant to the Offer to Purchase, a holder who validly delivers all or a portion of Notes in acceptance of the offer prior to 5:00 p.m., Eastern time, on April 22, 2009 and does not withdraw the Notes prior to 5:00 p.m., Eastern time, on April 23, 2009 will be entitled to receive cash equal to 100% of the principal amount of such Notes, plus any accrued and unpaid interest to, but excluding, the change of control purchase date.

The Notes currently are convertible. Holders may convert any outstanding Notes into the right to receive (x) $676.0817 in cash for each $1,000 principal amount of Notes based on the conversion price of $6.656 and conversion rate of 150.2404 that was in effect at the effective time of the merger and the $4.50 initial cash
'/>"/>

SOURCE Endo Pharmaceuticals Solutions Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PHILADELPHIA, May 24, 2013 -- High blood glucose is ... of intensive insulin therapy (IIT) to control hyperglycemia is ... does not show a consistent benefit and even shows ... the American College of Physicians, (ACP) Clinical Guidelines Committee ... the American Journal of Medical Quality . , ...
(Date:5/23/2013)... Littleton, CO (PRWEB) May 23, 2013 ... environment, Special Operations Forces and law enforcement need an ... Night Vision Security Enhancer, Night VISER , is ... illuminator and motion sensing system to increase border and ... for Night VISER have more than tripled over the ...
(Date:5/23/2013)... May 24, 2013 In his pulse-quickening novel, ... the question, “Do you trust your government?” , In the ... killed en route to London ’s Heathrow Airport. His ... is left waiting for him to arrive at his ... death surfaces, Alan has doubts about the government’s report. When ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
(Date:5/23/2013)... Branford, CT (PRWEB) May 23, 2013 ... patient satisfaction and perception management tools, and ASCA, ... to develop the new ASCA Benchmarking Program. ... in surveying technology and national benchmarking experience to ... with a comprehensive, state-of-the-art benchmarking tool. , “Voyance ...
Breaking Medicine News(10 mins):Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3
... Researchers at Cambridge University in the UK have discovered ... play a significant role in triggering breast cancer in ... new methods of targeting younger women at higher-than-average risk ... with mammography before they reach 50 - the age ...
... of 'monkey see, monkey do.' Researchers at Ohio University ... red, they began to develop red and orange skin and ... such as macaques and leaf monkeys, all have trichromatic vision, ... red colors. Primatologists have disagreed about whether this type of ...
... a say in how they quit are more likely to ... new research at the University of Rochester . ... the University of Rochester School of Medicine and Dentistry, will ... demonstrate patient involvement in a quit plan leads to smokers ...
... an enzyme called Cdk5 in their brains by using the ... adept at learning and quicker at figuring out the changes ... ,"Its pretty rare that you make mice smarter, so ... senior study author Dr. James Bibb, Assistant Professor of Psychiatry, ...
... Published today in the American Diabetes Association journal Diabetes ... that the care of elderly patients with type 1insulin ... facilities fails to meet ADA Standards of Care. ... Intensity of Care?, a study authored Jay Shubrook, D.O., ...
... are the bad guys that help bacterial pathogens do their ... system. In essence, they knock down the front door of ... ,Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
Cached Medicine News:Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3Health News:Color Vision Drove Primates to Develop Red Skin and Hair, Study Finds 2Health News:Choice is a Key Element in Success for Smokers Who Want to Quit 2Health News:Scientist Found New Mechanism for Brain Learning 2Health News:Diabetics in Nursing Homes Need Improved Care 2Health News:Diabetics in Nursing Homes Need Improved Care 3Health News:How Plague-Causing Bacteria Disarm Host Defense 2
(Date:5/24/2013)... China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... in China , today announced that ... issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai ... that on May 21, 2013, Ms. Siu ... shareholders of the Company, and her spouse, Mr. Tung ...
(Date:5/24/2013)... , May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... will participate in the Deutsche Bank Health Care Conference ... Waterfront Hotel.  Mr. Adrian Adams , ... an overview of the Company and its product pipeline ...   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
(Date:5/24/2013)... YORK , May 24, 2013 In accordance ... Rules and Rule 14e-1 of the United States Exchange Act, ... its original offer for Elan Corporation (NYSE: ELN). ... Limited ("Royalty Pharma") made an offer for the entire of ... Corporation, plc ("Elan") (the "Original Offer").  On ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... InfoLogix, Inc. (Pink Sheets: IFLG ), ... the healthcare and commercial industries, announced today that it ... Faire and Regional Conference, sponsored by HIMSS South Florida ... Grand Hotel in Davies, FL (situated North of Miami) ...
... Mass., Oct. 25 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), ... and development, focusing on the early diagnosis and preventive ... it has been selected by Windhover as one of ... the cardiovascular/metabolic category. This announcement is part of the ...
Cached Medicine Technology:InfoLogix to Present at South Florida Healthcare Trade Faire & Regional Conference 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3
... designed specifically for posteror ... injection of silicone oil ... Special high pressure tubing ... cannula. May also be ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Stainless steel probes, 23G x4 1/2in (.60mm x 11cm) Silicone tubing, length 14in (35cm), ID: .012in (.30mm) OD: .025in (.60mm...
...
Medicine Products: